Merrick I. Ross, MD
At the 7th European Post-Chicago Melanoma/Skin Cancer Meeting, Merrick I. Ross, MD, lectured on key issues in the evolving paradigm of melanoma care.
during the meeting, Ross, Charles M. McBride Distinguished Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, shared his thoughts on ongoing challenges in melanoma, including treating liver metastases, the diminished yet important role of surgery, and the need for better biomarkers.
OncLive: Can you discuss your presentation on liver metastases in melanoma?
: We have a very active multidisciplinary program at MD Anderson. I was invited to [Post-Chicago Melanoma] to talk about a couple different topics—one of them has to do with how to treat liver metastases for melanoma. It is a very difficult problem for a variety of reasons, one being that it is possible that the liver is somewhat of a sanctuary, and the very active immunotherapeutic agents may not be as effective in the liver. Although we certainly see responses with the PD-1 therapies and the combination with ipilimumab (Yervoy), generally speaking, it doesn’t seem like that disease responds as well as some other sites.
... to read the full story